Hydroxyurea for the treatment of sickle cell anemia.

@article{Platt2008HydroxyureaFT,
  title={Hydroxyurea for the treatment of sickle cell anemia.},
  author={Orah S. Platt},
  journal={The New England journal of medicine},
  year={2008},
  volume={358 13},
  pages={
          1362-9
        }
}
  • Orah S. Platt
  • Published 2008
  • Medicine
  • The New England journal of medicine
  • An 18-year-old woman with sickle cell anemia presents with recurrent painful crises, and treatment with hydroxyurea is recommended. Hydroxyurea causes a shift toward the production of red cells containing fetal hemoglobin. A possible increase in the risk of acute leukemia due to hydroxyurea therapy remains the subject of debate. 

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    The purpose of this study is to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic effects of Aes-103 (active ingredient 5-hydroxymethyl-2-furfural [5-HMF… Expand
    ConditionsSickle Cell Disease
    InterventionDrug

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 266 CITATIONS, ESTIMATED 56% COVERAGE

    FILTER CITATIONS BY YEAR

    2008
    2020

    CITATION STATISTICS

    • 13 Highly Influenced Citations

    • Averaged 21 Citations per year from 2018 through 2020

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 50 REFERENCES